Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132307) titled 'Clinical Study of Efficacy and Safety of Pitobrutinib Monotherapy for CD19 or CD22Negative Relapse After CD19/CD22Targeted Immunotherapy in Patients With Acute BLymphoblastic Leukemia' on Sept. 11.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Condition:
Acute Blymphoblastic leukemia
Intervention:
Intervention group:Patients will be treated with pitobutinib at a dose of 200 mg per day
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-09-15
Target Sample Size: Intervention ...